Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCP | P55072 | 1/20 | 0.43 |
| ▸ | IGF1R | P08069 | 8/20 | 0.41 |
| ▸ | ALK | Q9UM73 | 7/20 | 0.41 |
| ▸ | INSR | P06213 | 6/20 | 0.41 |
| ▸ | FYN | P06241 | 3/20 | 0.41 |
| ▸ | PTK2 | Q05397 | 3/20 | 0.41 |
| ▸ | BMPR1B | O00238 | 2/20 | 0.41 |
| ▸ | PLK4 | O00444 | 2/20 | 0.41 |
| ▸ | GAK | O14976 | 2/20 | 0.41 |
| ▸ | ERN1 | O75460 | 2/20 | 0.41 |
| ▸ | STK10 | O94804 | 2/20 | 0.41 |
| ▸ | ABL1 | P00519 | 2/20 | 0.41 |
| ▸ | EGFR | P00533 | 2/20 | 0.41 |
| ▸ | LCK | P06239 | 2/20 | 0.41 |
| ▸ | FES | P07332 | 2/20 | 0.41 |
| ▸ | YES1 | P07947 | 2/20 | 0.41 |
| ▸ | HCK | P08631 | 2/20 | 0.41 |
| ▸ | ROS1 | P08922 | 2/20 | 0.41 |
| ▸ | FER | P16591 | 2/20 | 0.41 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10205071 | 0.90 | L3MBTL3 (0.46) | IGF1RALKINSRPTK2L3MBTL3 | |
| SCHEMBL27039118 | 0.87 | VCP (0.43) | VCPIGF1RALKINSRFYN | |
| SCHEMBL310368 | 0.87 | ALDH1A1 (0.49) | IGF1RALKFYNPTK2BKHK | |
| SCHEMBL2209498 | 0.87 | ALDH1A1 (0.49) | IGF1RALKFYNPTK2BKHK | |
| SCHEMBL517468 | 0.86 | ALK (0.50) | IGF1RALKINSRFYNPTK2 | |
| SCHEMBL520836 | 0.86 | L3MBTL1 (0.57) | IGF1RALKINSREGFRL3MBTL3 | |
| SCHEMBL10206202 | 0.86 | L3MBTL3 (0.53) | IGF1RALKINSREGFRL3MBTL3 | |
| SCHEMBL30340719 | 0.86 | KHK (0.46) | KHKKDM4EALDH1A1TSHR | |
| SCHEMBL309548 | 0.85 | L3MBTL1 (0.55) | ABL1L3MBTL3L3MBTL1ALDH1A1MAPT | |
| SCHEMBL13981638 | 0.85 | L3MBTL1 (0.55) | ABL1L3MBTL3L3MBTL1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2601186-A2 | 4-(1H-INDOL-3-YL)-PYRIMIDINES AS ALK INHIBITORS | AstraZeneca AB (SE) | 2013-06-12 | — | — | EP | disclosed |
| CN-103153982-A | 4-(1H-Indol-3-yl) -pyrimidines as ALK inhibitors | ASTRAZENECA AB | 2013-06-12 | — | — | CN | disclosed |
| US-8461170-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2013-06-11 | — | — | US | disclosed |
| US-8461170-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2013-06-11 | — | — | US | disclosed |
| US-8461170-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2013-06-11 | — | — | US | disclosed |
| WO-2012017239-A2 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2012-02-09 | — | — | WO | disclosed |
| WO-2012017239-A2 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2012-02-09 | — | — | WO | disclosed |
| US-20120028924-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2012-02-02 | — | — | US | disclosed |
| US-20120028924-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2012-02-02 | — | — | US | disclosed |
| US-20120028924-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028924-A1 | CHEMICAL COMPOUNDS | ALK, BRAF, ABL1 | VCP 3827/4885IGF1R 499/4885ALK 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.